Profile data is unavailable for this security.
About the company
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's through a royalty-bearing exclusive worldwide license from the Licensor.
- Revenue in USD (TTM)0.00
- Net income in USD-15.16m
- Incorporated2016
- Employees4.00
- LocationAlzamend Neuro Inc3480 Peachtree Road NE, Second Floor, Suite 103ATLANTA 30326United StatesUSA
- Phone+1 (302) 636-5400
- Fax+1 (302) 636-5454
- Websitehttps://alzamend.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Processa Pharmaceuticals Inc | 0.00 | -11.12m | 4.63m | 13.00 | -- | 0.4176 | -- | -- | -8.72 | -8.72 | 0.00 | 3.88 | 0.00 | -- | -- | 0.00 | -154.40 | -84.35 | -175.45 | -90.03 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 59.45 | -- | -34.05 | -- |
| Zyversa Therapeutics Inc | 0.00 | -106.25m | 4.63m | 7.00 | -- | 0.2232 | -- | -- | -192.29 | -192.29 | 0.00 | 2.73 | 0.00 | -- | -- | 0.00 | -139.81 | -- | -160.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -340.15 | -- | -- | -- |
| China Pharma Holdings Inc | 7.01m | -3.08m | 4.67m | 231.00 | -- | 0.449 | -- | 0.6657 | -1.06 | -1.06 | 2.07 | 0.7016 | 0.4094 | 2.18 | 15.14 | 30,351.95 | -17.98 | -29.66 | -41.91 | -55.25 | -4.01 | 6.47 | -43.91 | -73.09 | 0.332 | -8.42 | 0.3121 | -- | -13.48 | -10.68 | 22.50 | -- | -25.78 | -- |
| Lipella Pharmaceuticals Inc | 449.62k | -4.62m | 4.81m | 5.00 | -- | 1.37 | -- | 10.70 | -0.7858 | -0.7858 | 0.0749 | 0.5194 | 0.0944 | -- | 6.16 | 89,924.00 | -96.96 | -- | -116.00 | -- | -- | -- | -1,027.31 | -- | -- | -- | 0.00 | -- | 144.15 | -- | -77.81 | -- | -- | -- |
| Alzamend Neuro Inc | 0.00 | -15.16m | 4.87m | 4.00 | -- | -- | -- | -- | -2.32 | -2.32 | 0.00 | -0.4146 | 0.00 | -- | -- | 0.00 | -265.85 | -- | -496.81 | -- | -- | -- | -- | -- | -- | -1,736.10 | -- | -- | -- | -- | -20.35 | -- | -- | -- |
| Oragenics Inc | 37.65k | -20.66m | 4.88m | 5.00 | -- | 2.13 | -- | 129.72 | -8.69 | -8.69 | 0.0167 | 1.03 | 0.0038 | -- | -- | 7,530.00 | -209.44 | -97.60 | -252.98 | -106.24 | -- | -- | -54,862.55 | -36,169.75 | -- | -- | 0.0898 | -- | -71.37 | -- | -44.56 | -- | 51.64 | -- |
| Shineco Inc | 4.50m | -13.99m | 4.92m | 87.00 | -- | 0.0126 | -- | 1.09 | -3.93 | -4.63 | 0.4431 | 60.93 | 0.0558 | 0.3932 | 0.9844 | 51,761.38 | -18.99 | -12.77 | -34.44 | -16.84 | 11.94 | 25.88 | -340.48 | -102.06 | 0.4903 | -9.04 | 0.3792 | -- | -- | -58.35 | -33.86 | -- | -- | -- |
| NLS Pharmaceutics AG | 0.00 | -15.47m | 4.95m | 2.00 | -- | -- | -- | -- | -0.534 | -0.534 | 0.00 | -0.1322 | 0.00 | -- | -- | 0.00 | -714.74 | -308.05 | -- | -- | -- | -- | -- | -- | -- | -175.42 | -- | -- | -- | -- | -38.08 | -- | -- | -- |
| Synaptogenix Inc | 0.00 | -13.78m | 4.95m | 5.00 | -- | 0.1805 | -- | -- | -43.56 | -43.56 | 0.00 | 26.55 | 0.00 | -- | -- | 0.00 | -17.32 | -40.33 | -18.83 | -43.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -142.17 | -- | -3.21 | -- |
| Portage Biotech Inc | 0.00 | -144.90m | 4.95m | 7.00 | -- | 0.1546 | -- | -- | -7.96 | -7.96 | 0.00 | 1.62 | 0.00 | -- | -- | 0.00 | -111.60 | -19.70 | -113.27 | -26.48 | -- | -- | -- | -- | -- | -- | 0.0087 | -- | -- | -- | -520.10 | -- | -- | -- |
| GT Biopharma Inc | 0.00 | -7.60m | 5.04m | 2.00 | -- | 0.6742 | -- | -- | -5.57 | -5.57 | 0.00 | 5.41 | 0.00 | -- | -- | 0.00 | -49.26 | -205.36 | -78.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 63.62 | -- | -- | -- |
| Alterola Biotech Inc | 0.00 | -2.88m | 5.05m | 1.00 | -- | -- | -- | -- | -0.0027 | -0.0027 | 0.00 | -0.001 | 0.00 | -- | -- | 0.00 | -47.24 | -- | -63.88 | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -- | -- | 73.07 | -- | -- | -- |
| Halberd Corp | 281.24k | 25.34k | 5.09m | 3.00 | 3.45 | -- | 200.51 | 18.09 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
| PaxMedica Inc | 0.00 | -18.29m | 5.17m | 6.00 | -- | 1.51 | -- | -- | -15.85 | -15.85 | 0.00 | 0.4574 | 0.00 | -- | -- | 0.00 | -463.93 | -755.77 | -915.89 | -- | -- | -- | -- | -- | -- | -1,760.66 | 0.00 | -- | -- | -- | -23.56 | -- | -- | -- |
| Cannabis Bioscience Internatnl Hlgs Inc | 56.94m | 6.94m | 5.22m | 389.00 | 0.0009 | 0.0001 | 0.5654 | 0.0916 | 0.5328 | 0.5328 | 4.29 | 4.92 | 0.5917 | 62.81 | 1.45 | 146,384.30 | 7.83 | -- | 11.73 | -- | 31.96 | -- | 13.24 | -- | 0.6856 | 50.75 | 0.0631 | -- | 12.79 | -- | 177.84 | -- | -- | -- |
Data as of Apr 24 2024. Currency figures normalised to Alzamend Neuro Inc's reporting currency: US Dollar USD
5.45%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Truist Bank (Private Banking)as of 31 Dec 2023 | 154.33k | 2.25% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 78.55k | 1.14% |
| Geode Capital Management LLCas of 31 Dec 2023 | 52.40k | 0.76% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 39.74k | 0.58% |
| HRT Financial LLCas of 31 Dec 2023 | 16.81k | 0.25% |
| RFG Advisory LLCas of 31 Mar 2024 | 16.67k | 0.24% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 10.19k | 0.15% |
| Tower Research Capital LLCas of 31 Dec 2023 | 3.32k | 0.05% |
| UBS Securities LLCas of 31 Dec 2023 | 1.91k | 0.03% |
| Harbor Investment Advisory LLCas of 31 Mar 2024 | 200.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
